Press release Communiqué de presse
Press release Communiqué de presse
July 28, 2006 28 July, 2006
Business Advisory Board Established to Commercialize Diabetes Product
Kelowna, B.C. -- Pheromone Sciences Corp.
("Pheromone") is pleased to announce that it has
established a Business Advisory Board to
guide the directors and management in
the Company's diabetes product. Pheromone
appointed three former Company directors to the
William Milligan, Andrew Saxton and Christopher
"These men all have an intimate understanding of the Company and the business of biotechnology," said Dr. William Cochrane, Chairman of the Board of Directors. "We are glad Pheromone will continue to get the benefit of their expertise and wisdom."
About William Milligan Since 2002 Mr. Milligan has served as the Chief Business Officer of Migenix Inc. (TSX: MGI), a biopharmaceutical company focused on innovative drugs for life- threatening diseases. He has extensive experience in leading and managing pharmaceutical commercialization, financing, product development, licensing and strategic alliances from both large pharmaceutical and small biotechnology companies. Mr. Milligan was previously President & CEO of Cytran Inc., a private biotechnology company based in Seattle, and CEO of Intellivax International Inc., a private biotechnology company based in Montreal and Baltimore. Prior to that he worked for Hoffmann-La Roche Ltd. (Canada) and Eli Lilly Inc. (Canada). At Roche, he held Vice President positions in Pharmaceuticals including: Business Development and New Product Planning, Sales Division, and Biomedical Division. Mr. Milligan served as a Director of Pheromone from 2000-2006.
About Andrew Saxton Mr. Saxton is currently Chairman of the King George Financial Corporation and has had a long and successful career of leadership roles in finance, commercial real estate and insurance. He is currently a Director of Canadian Commercial Corporation (a Federal Crown Corporation), Earthworks Industries Inc., Imperial Parking Canada Corporation, and the University of British Columbia Investment Management Trust. He was previously the co-founder and Executive Vice President of Laurentide Financial Corporation, founder and President of Elite Insurance and Chairman of Grouse Mountain Resorts Ltd. He has been a Director with of several companies including BCTV, the Commonwealth Bank of Nassau Bahamas, and the Insurance Corporation of British Columbia, where he chaired the Investment Committee. He has served on many advisory boards including the World Heart Federation, the BC Life Sciences Fund and the Dean of Faculty of Medicine's Community Advisory board at the University of British Columbia. From 2000- 2006 Mr. Saxton was a director of Pheromone.
About Christopher Neuman Mr. Neuman was a director of Pheromone from 2000 to 2006, serving as its CEO until 2005. He has 35 years experience in the Canadian health care industry, including positions as General Manager of ALZA Canada, and President and General Manager of Baker Cummins Inc. He held senior management positions with Marion Merrell Dow Inc., PharmaScience Inc., Boots Pharmaceuticals Ltd. and Neuromedical Systems Inc., where, as General Manager, he was responsible for the establishment of a Canadian subsidiary for the U.S. diagnostics company. His early career included production & operations management, positions at Davis+Geck/Lederle Laboratories, Elliot-Marion Co. Ltd., and sales and sales & marketing management positions at Beecham Laboratories Inc.
Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.
ON BEHALF OF THE BOARD
Dev Randhawa, CEO
For further information contact: Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493